nitroblue tetrazolium has been researched along with losartan in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrario, CM; Gallagher, PE; Ganten, D; Strawn, WB; Tallant, EA | 1 |
1 other study(ies) available for nitroblue tetrazolium and losartan
| Article | Year |
|---|---|
Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Cell Count; Blood Pressure; Cell Adhesion; Endothelium, Vascular; Female; Heart Rate; Hematocrit; Hydralazine; Hypertension; Losartan; Male; Monocytes; Nitroblue Tetrazolium; Peptide Fragments; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System | 1999 |